Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1200 in Advanced Solid Tumors
NCT06242691Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2024
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 6
01
Overview
A Phase 2 trial of lucansatuzumab in solid tumor, gastric cancer (GC), esophageal cancer, biliary tract cancer (BTC), pancreatic ductal adenocarcinoma (PDAC), sponsored by Merck & Co.. Started Feb 2024; status: completed.
02
Drugs
lucansatuzumab
03
Conditions
solid tumorgastric cancer (GC)esophageal cancerbiliary tract cancer (BTC)pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06242691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06242691.